NASDAQ: MDXHMdxhealth Sa Stock
$3.37+0.17 (+5.31%)
Updated Mar 16, 2026
MDXH Price
$3.37
Fair Value Price
N/A
Market Cap
$16.68M
52 Week Low
$1.36
52 Week High
$5.33
P/E
-0.5x
P/B
-1.38x
P/S
0.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$107.88M
Earnings
-$33.52M
Gross Margin
64.5%
Operating Margin
-13.36%
Profit Margin
-31.1%
Debt to Equity
-13.23
Operating Cash Flow
-$2M
Beta
0.58
Next Earnings
May 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MDXH Overview
MDxHealth SA (formerly OncoMethylome Sciences SA) provides urologic solutions in the U.S. and internationally. OFferings include SelectMDx (a prostate cancer genomic testing solution), a non-invasive urine test, and ConfirmMDx, an epigenetic test that provide a clinical pathway to identify clinically prostate cancer using mimimally invasive procedures. MDxHealth was incorporated in 2003 and is headquartered in Herstal, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDXH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
MDXH
Ranked#36 of 43
Ranked#36 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $119.28 | A | |
| $13.57 | A | |
| $71.34 | B |
Be the first to know about important MDXH news, forecast changes, insider trades & much more!
MDXH News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDXH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDXH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDXH is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MDXH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MDXH due diligence checks available for Premium users.
Valuation
MDXH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.5x
Industry
16.31x
Market
32.08x
MDXH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.38x
Industry
3.64x
MDXH's financial health
Profit margin
Revenue
$29.5M
Net Income
-$8.9M
Profit Margin
-30.2%
MDXH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MDXH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$148.0M
Liabilities
$160.0M
Debt to equity
-13.23
MDXH's short-term assets ($53.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDXH's long-term liabilities ($110.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDXH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDXH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$378.0k
Investing
$1.8M
Financing
-$5.2M
MDXH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDXH vs Diagnostic & Research Stocks
Mdxhealth Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.